Serum uric acid, Hyperuricemia, Exercise capacity, Heart failure, Prevalence


Hyperuricemia (HU) is important and common comorbidity that often coexist in patients with heart failure (HF). High values of serum uric acid are associated to severe heart failure. The purpose of the present study was to evaluate a UA-lowering and prognostic effects of allopurinol in patients with chronic HF and hyperuricemia.We studied 75 patients with HF and increased UA levels, who have been admitted to hospital. All patients aged 18 years and older were eligible, provided a left ventricular ejection fraction of 45% or less was documented on echocardiography during the enrolment visit and signs and symptoms of chronic heart failure were present. Patient baseline assessment included a standardized HF history regarding HF aetiology (classified as ischemic or non-ischemic) and co-morbidities. All patients underwent a standardized clinical evaluation, including physical examination, determination of NYHA class, determination of body weight. Blood samples were drawn from an antecubital vein in the morning for the assessment of a full blood count and clinical chemistry. Patients were divided in to two groups:  50 patients (group 1) received allopurinol. The initial dose of in most patients was 200 mg/day and it was reduced according to their renal function or UA level. 25 patients (group 2) – controlled group. Treatment duration was 6 months.Repeated studies after 3 months showed the following results: Uric acid treatment improved the echocardiographic parameters (LVEF, LV mass index, IVS, PW, stroke volume), reduced NT- proBNP, improved renal function, Improved NYHA functional class;6-minute walking test distance improved significantly in the UA- treatment group and quality of life. The QoL parameters that was improved included reduced physical limitation, improved mobility, selfcare, increased daily activities and reduced discomfort, anxiety and depression.Among patients with HF and elevated serum uric acid levels, allopurinol use was safe and strongly associated with improved outcomes.


Download data is not yet available.


Hamaguchi S, Furumoto T, Tsuchihashi-Makaya M et al (2011) Hyperuricemia predicts adverse outcomes in patients with heart failure. Int J Cardiol 151:143–147. https://doi.org/10.1016/j.ijcard. 2010.05.002 45

Ogino K, Kato M, Furuse Y, Kinugasa Y, Ishida K, Osaki S, et al. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. Circ Heart fail 2010; 3:73-81. doi: 10.1161/CIRCHEARTFAILURE.109.868604

Roger VL. Epidemiology of heart failure. Circ Res 2013; 113:646-659. doi: 10.1161/CIRCRESAHA.113.300268

Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003; 107:1991-1997. doi: 10.1161/01.CIR.0000065637.10517.AD

Huang H, Huang B, Li Y, Huang Y, Li J, Yao H, et al. Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart fail 2014; 16:15-24. doi: 10.1093/eurjhf/hft132

Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62: e147–e239.

Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18: 891–975.

Van Der Pol A, Van Gilst WH, Voors AA, et al. Treating oxidative stress in heart failure: past, present and future. Eur J Heart Fail 2019; 21: 425–435.

Ayoub KF, Pothineni NVK, Rutland J, et al. Immunity, Inflammation, and Oxidative Stress in Heart Failure: Emerging Molecular Targets. Cardiovasc Drugs Ther 2017; 31: 593–608.

Takeishi Y. Biomarkers in heart failure. Int Heart J 2014; 55: 474–481.

Suzuki S, Shishido T, Funayama A, et al. Long pentraxin PTX3 exacerbates pressure overload-induced left ventricular dysfunction. PLoS One 2013; 8: e53133.

Suzuki S, Shishido T, Ishino M, et al. 8- Hydroxy-20 -deoxyguanosine is a prognostic mediator for cardiac event. Eur J Clin Invest 2011; 41: 759–766.

Koyama Y, Takeishi Y, Arimoto T, et al. High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure. J Card Fail 2007; 13: 199–206.

McCord JM and Fridovich I. The reduction of cytochrome c by milk xanthine oxidase. J Biol Chem 1968; 243: 5753–5760.

Landmesser U, Spiekermann S, Dikalov S, et al. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 2002; 106: 3073–3078.

Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006; 58(1):87-114

Amado LC, Saliaris AP, Raju SVY, et al. Xanthine oxidase inhibition ameliorates cardiovascular dysfunction in dogs with pacing-induced heart failure. J Mol Cell Cardiol. 2005; 39(3):531-536

Mellin V, Isabelle M, Oudot A, et al. Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure. Eur Heart J. 2005; 26(15):1544-1550.

Minhas KM, Saraiva RM, Schuleri KH, et al. Xanthine oxidoreductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy. Circ Res. 2006; 98(2):271-279.

Stull LB, Leppo MK, Szweda L, Gao WD, Marban E. Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy. Circ Res. 2004;95(10):1005-1011.

Ichiro Hisatom, Peili Li, Fikri Taufiq et al. Hyperuricemia as a Risk Factor for Cardiovascular Diseases. Journal of Biomedicine and Translational Research, 6 (3) 2020, 101-109

Fang X, Pan C, Chen Y, et al. Assessment of subclinical left ventricular changes in essential hypertensive patients with hyperuricemia: A three-dimensional speckle-tracking echocardiography study. Clin Exp Hypertens 2017; 39: 93–99.

Jankowska EA, Ponikowska B, Majda J, et al. Hyperuricaemia predicts poor outcome in patients with mild to moderate chronic heart failure. Int J Cardiol 2007; 115: 151–155.

Pascual-Figal DA, Hurtado-Martınez JA, Redondo B, et al. Hyperuricaemia and long-term outcome after hospital discharge in acute heart failure patients. Eur J Heart Fail 2007; 9: 518–524.




How to Cite

KETEVAN SANIKIDZE, IRMA MAMATSASHVILI, & SHALVA PETRIASHVILI. (2022). URIC ACID LOWERING TREATMENT OF PATIENTS WITH CHRONIC HEART FAILURE. Experimental and Clinical Medicine Georgia, (4). https://doi.org/10.52340/jecm.2022.06.12




Most read articles by the same author(s)

Similar Articles

1 2 3 4 5 6 7 8 9 > >> 

You may also start an advanced similarity search for this article.